FDA panel declines to endorse diabetes drug dapagliflozin

07/19/2011 | Reuters

A panel of FDA advisers voted 9-6 against endorsing the approval of dapagliflozin, Bristol-Myers Squibb and AstraZeneca's drug candidate for type 2 diabetes. Advisers said clinical data do not provide substantial evidence of dapagliflozin's efficacy and risks.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA